Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Non-Current Deferred Tax Liability (2018 - 2025)

Historic Non-Current Deferred Tax Liability for Innate Pharma (IPHA) over the last 8 years, with Q2 2025 value amounting to $11.6 million.

  • Innate Pharma's Non-Current Deferred Tax Liability rose 1826.04% to $11.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $11.6 million, marking a year-over-year increase of 1826.04%. This contributed to the annual value of $9.7 million for FY2023, which is 1144.51% up from last year.
  • Latest data reveals that Innate Pharma reported Non-Current Deferred Tax Liability of $11.6 million as of Q2 2025, which was up 1826.04% from $9.8 million recorded in Q2 2024.
  • Innate Pharma's 5-year Non-Current Deferred Tax Liability high stood at $11.6 million for Q2 2025, and its period low was $5.8 million during Q4 2021.
  • Its 5-year average for Non-Current Deferred Tax Liability is $8.9 million, with a median of $9.2 million in 2023.
  • In the last 5 years, Innate Pharma's Non-Current Deferred Tax Liability tumbled by 9948.75% in 2021 and then surged by 5197.59% in 2022.
  • Over the past 5 years, Innate Pharma's Non-Current Deferred Tax Liability (Quarter) stood at $5.8 million in 2021, then surged by 51.98% to $8.7 million in 2022, then grew by 10.85% to $9.7 million in 2023, then rose by 1.39% to $9.8 million in 2024, then grew by 18.26% to $11.6 million in 2025.
  • Its Non-Current Deferred Tax Liability was $11.6 million in Q2 2025, compared to $9.8 million in Q2 2024 and $9.7 million in Q4 2023.